Lung cancer management in 2010.

Apar Kishor Ganti, Chao H. Huang, Mark A. Klein, Sean Keefe, Michael J. Kelley

Research output: Contribution to journalArticle

Abstract

The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalOncology (Williston Park, N.Y.)
Volume25
Issue number1
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Lung Neoplasms
Cytotoxins
Patient Care
Clinical Trials
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ganti, A. K., Huang, C. H., Klein, M. A., Keefe, S., & Kelley, M. J. (2011). Lung cancer management in 2010. Oncology (Williston Park, N.Y.), 25(1), 64-73.

Lung cancer management in 2010. / Ganti, Apar Kishor; Huang, Chao H.; Klein, Mark A.; Keefe, Sean; Kelley, Michael J.

In: Oncology (Williston Park, N.Y.), Vol. 25, No. 1, 01.2011, p. 64-73.

Research output: Contribution to journalArticle

Ganti, AK, Huang, CH, Klein, MA, Keefe, S & Kelley, MJ 2011, 'Lung cancer management in 2010.', Oncology (Williston Park, N.Y.), vol. 25, no. 1, pp. 64-73.
Ganti AK, Huang CH, Klein MA, Keefe S, Kelley MJ. Lung cancer management in 2010. Oncology (Williston Park, N.Y.). 2011 Jan;25(1):64-73.
Ganti, Apar Kishor ; Huang, Chao H. ; Klein, Mark A. ; Keefe, Sean ; Kelley, Michael J. / Lung cancer management in 2010. In: Oncology (Williston Park, N.Y.). 2011 ; Vol. 25, No. 1. pp. 64-73.
@article{ac3215efc4444008a8439b885dc28170,
title = "Lung cancer management in 2010.",
abstract = "The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.",
author = "Ganti, {Apar Kishor} and Huang, {Chao H.} and Klein, {Mark A.} and Sean Keefe and Kelley, {Michael J.}",
year = "2011",
month = "1",
language = "English (US)",
volume = "25",
pages = "64--73",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Lung cancer management in 2010.

AU - Ganti, Apar Kishor

AU - Huang, Chao H.

AU - Klein, Mark A.

AU - Keefe, Sean

AU - Kelley, Michael J.

PY - 2011/1

Y1 - 2011/1

N2 - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

AB - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=79952785345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952785345&partnerID=8YFLogxK

M3 - Article

C2 - 21361246

VL - 25

SP - 64

EP - 73

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -